Rochemaure J, Lehert P, Sauvaget J, Robillard M, Betbeder-Matibet A
Hôtel-Dieu de Paris.
Rev Pneumol Clin. 1988;44(1):43-7.
Fifty-six patients with recurrent bronchopulmonary infections associated with chronic bronchitis were randomly allocated to 2 groups, to assess whether treatment with an immunomodulator, Diribiotin CK, could enhance resistance to infection. The double-blind, placebo-controlled prospective trial over a 9 month period showed that this immunomodulator was well tolerated and significantly reduced the rate of respiratory tract infection. The drug also significantly reduced the prescribing of antibiotic medication and the rate of absenteism from work. These effects have been demonstrated in a rigorously designed clinical study. This is the first time that a clear clinical activity has been attributed to an inducer of soluble mediators of immunity.
56例患有与慢性支气管炎相关的复发性支气管肺部感染的患者被随机分为两组，以评估免疫调节剂Diribiotin CK治疗是否能增强抗感染能力。这项为期9个月的双盲、安慰剂对照前瞻性试验表明，这种免疫调节剂耐受性良好，可显著降低呼吸道感染率。该药物还显著减少了抗生素的处方量以及缺勤率。这些效果已在一项设计严谨的临床研究中得到证实。这是首次明确将临床活性归因于免疫可溶性介质诱导剂。
